HC Wainwright & Co. Lowers Tenaya Therapeutics' Price Target to $3.00

HC Wainwright & Co. lowered the price target for Tenaya Therapeutics (TNYA) from $5.00 to $3.00, a 40% decrease, while maintaining its "Buy" rating. The firm cited evolving market conditions as the reason for the adjustment. Tenaya Therapeutics is a preclinical stage biotechnology company focused on heart disease therapies. The average target price for TNYA is $9.71 with a high estimate of $40.00 and a low estimate of $3.00.